ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need.With four internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietary kinase library from which to select additional drug candidates, ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy. ArQule is led by a senior management team with significant clinical and commercial expertise that provides the leadership required to optimize its opportunities for success in a rapidly changing and highly competitive field. Source
No articles found.
We exist to make the first step in a familys path to recovery the right step thro...
We exist to make the first step in a familys p...
Soliton, Inc. is a medical device company with a novel and proprietary platform te...
Soliton, Inc. is a medical device company with ...
Inovalon is a leading technology company providing cloud-based platforms empowerin...
Inovalon is a leading technology company provid...
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...
UNITY Biotechnology is developing therapeutics ...
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company fo...
Portola Pharmaceuticals is a global, commercial...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
Join the National Investor Network and get the latest information with your interests in mind.